To provide optimal patient care, VHA hematologists, oncologists, nurses, pharmacists, and other health care professionals must be prepared with a comprehensive understanding of the appropriate treatment of patients with MCL and the clinical utility of agents that could significantly impact patient outcomes. The use of BTK inhibitors as frontline therapy represents a novel approach that could benefit many veterans with MCL, including those who would otherwise have a poor prognosis. VHA clinicians must be aware of the clinical data supporting various BTKi combinations and strategies, as well as the options for formulary and non-formulary access, unique characteristics, benefits and risks of each agent. Expert insights from faculty specializing in this relatively rare lymphoma will support VHA oncologists in their quest to improve patient outcomes.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 384 Inverness Parkway
Pricing
All courses included · from $18.75/mo
Courses are included in the subscription; some are also sold individually.
| Student Flex | $18.75/mo |
| Professional Flex | $60/mo |
| Student 3-Year | $100 |
| Student 2-Year | $112.50 |
+4 more plans
Collected from the provider’s public pages · source
Specialties served/covered
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Maternal-Fetal Medicine
- Medical Leadership & Administration
- Medical Oncology
- Mood & Anxiety Disorders
- Nephrology
- Neurocritical Care
- Neurodevelopmental Disabilities
- Neurology
- Neuroradiology
- Nuclear Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Plastic & Reconstructive Surgery
- Practice Management & Ethics
- Pulmonary Disease
- Sleep Medicine
- Surgical Oncology
- Thoracic Anesthesia
- Urological Oncology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Conference / congress
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedDec 19, 2025
-
Last day to claim creditDec 20, 2026 2 months left
-
Plexus Communications +1 Bringing BTK Inhibitors to the Frontline Setting: Essential Advancements in Mantle Cell Lymphoma Management
-
Plexus Communications +1 Advancing Metastatic NSCLC: The Role of HER2- and TROP2-Targeted Antibody-Drug Conjugates
-
Plexus Communications +1 VHA Oncology Clinical Forums: Optimizing BTK Inhibitor Use in the Management of Veterans With Chronic Lymphocytic Leukemia
-
HealthTree Foundation for Chronic Lymphocytic Leukemia +1 FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment
-
Creative Educational Concepts, Inc. AI-Powered Precision Learning: Optimizing Frontline Treatment Decision-Making in Chronic Lymphocytic Leukemia: Integrating Biomarkers, Clinical Evidence, and Patient-Centered Care
-
National Comprehensive Cancer Network Recorded Presentation from Optimizing Patient Outcomes: The Changing Treatment Paradigm for Mantle Cell Lymphoma: Improving the Prognosis with Targeted Inhibitors and Evolving Immunotherapy Options
